Alzheimer’s - Articles and news items

Alzheimer's disease definition

AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer’s disease

Industry news / 23 August 2016 / AstraZeneca

AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.

FDA approves expanded label for Namzaric in Alzheimer’s disease

Industry news / 20 July 2016 / Victoria White, Digital Content Producer

Namzaric is a fixed-dose combination of memantine hydrochloride, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor…

Trial of RVT-101 in Alzheimer’s disease starts at Plymouth Science Park

Industry news / 11 July 2016 / Victoria White, Digital Content Producer

If approved, RVT-101 could be the first Alzheimer’s treatment in 14 years. The last drug to be approved to help improve cognition was Donepezil in 2002…

Investigational Alzheimer’s treatment Aducanumab accepted into EMA’s PRIME programme

Industry news / 2 June 2016 / Victoria White, Digital Content Producer

PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines…

Phase II/III trial of AZD3293 in early Alzheimer’s disease to continue

Industry news / 8 April 2016 / Victoria White

AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial…

Lilly changes the primary endpoint of the EXPEDITION3 Alzheimer’s trial

Industry news / 15 March 2016 / Victoria White

Lilly has made a change to the primary endpoint for the EXPEDITION3 clinical trial, a Phase 3 study of solanezumab in people with mild Alzheimer’s dementia…

Alzheimer’s disease treatment market to more than double by 2021, says GBI Research

Industry news / 11 February 2016 / Victoria White

GBI Research says the impressive growth in the treatment market will be primarily driven by increased disease prevalence during the forecast period…

European Pharmaceutical Review’s top 10 stories from 2015

Blog / 28 January 2016 / Victoria White, Digital Content Producer, European Pharmaceutical Review

2015 was an interesting year for the pharmaceutical industry. Here we pick a selection of the top stories that hit the headlines…

Aridhia’s data platform selected by EPAD for dementia prevention project

Industry news / 19 January 2016 / Victoria White

The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease…

MHRA helps make dementia medicine packaging more user-friendly

Industry news / 4 November 2015 / Victoria White

From June 2016, medicines for the treatment of dementia will include the days of the week clearly on the blister packs…

Donepezil may delay residential care for Alzheimer’s sufferers

Industry news / 27 October 2015 / Victoria White

Withdrawing donepezil from people in the advanced stages of Alzheimer’s disease doubles their risk of being placed in a nursing home within a year, according to a UCL study…

Resveratrol stabilises Alzheimer’s disease biomarker

Industry news / 14 September 2015 / Victoria White

Patients who were treated with increasing doses of resveratrol over 12 months showed little or no change in amyloid-beta40 (Abeta40) levels…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...